Novel Therapeutics Against Breast Cancer Stem Cells by Targeting Surface Markers and Signaling Pathways

被引:16
作者
Das, Plabon K. [1 ]
Rakib, Md. A. [1 ]
Khanam, Jahan A. [1 ]
Pillai, Suja [2 ]
Islam, Farhadul [1 ,2 ]
机构
[1] Univ Rajshahi, Dept Biochem & Mol Biol, Rajshahi 6205, Bangladesh
[2] Univ Queensland, Sch Biomed Sci, Fac Med, Brisbane, Qld, Australia
关键词
Breast cancer; BCSCs; surface markers; signaling pathways; therapeutic options; breast cancer; IN-VIVO; ALDEHYDE DEHYDROGENASE; COLORECTAL-CANCER; DRUG-RESISTANCE; UP-REGULATION; NOTCH; HYALURONAN; INHIBITION; HEDGEHOG; GENE;
D O I
10.2174/1574888X14666190628104721
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background: Breast cancer remains to be one of the deadliest forms of cancers, owing to the drug resistance and tumor relapse caused by breast cancer stem cells (BCSCs) despite notable advancements in radio-chemotherapies. Objectives: To find out novel therapeutics against breast cancer stem cells by aiming surface markers and signaling pathways. Methods: A systematic literature search was conducted through various electronic databases including, Pubmed, Scopus, Google scholar using the keywords "BCSCs, surface markers, signaling pathways and therapeutic options against breast cancer stem cell. Articles selected for the purpose of this review were reviewed and extensively analyzed. Results: Novel therapeutic strategies include targeting BCSCs surface markers and aberrantly activated signaling pathways or targeting their components, which play critical roles in self-renewal and defense, have been shown to be significantly effective against breast cancer. In this review, we represent a number of ways against BCSCs surface markers and hyper-activated signaling pathways to target this highly malicious entity of breast cancer more effectively in order to make a feasible and useful strategy for successful breast cancer treatment. In addition, we discuss some characteristics of BCSCs in disease progression and therapy resistance. Conclusion: BCSCs involved in cancer pathogenesis, therapy resistance and cancer recurrence. Thus, it is suggested that a multi-dimensional therapeutic approach by targeting surface markers and aberrantly activated signaling pathways of BCSCs alone or in combination with each other could really be worthwhile in the treatment of breast cancer.
引用
收藏
页码:669 / 682
页数:14
相关论文
共 124 条
[1]   Koenimbin, a natural dietary compound of Murraya koenigii (L) Spreng: inhibition of MCF7 breast cancer cells and targeting of derived MCF7 breast cancer stem cells (CD44+/CD24-/low): an in vitro study [J].
Ahmadipour, Fatemeh ;
Noordin, Mohamed Ibrahim ;
Mohan, Syam ;
Arya, Aditya ;
Paydar, Mohammadjavad ;
Looi, Chung Yeng ;
Keong, Yeap Swee ;
Siyamak, Ebrahimi Nigjeh ;
Fani, Somayeh ;
Firoozi, Maryam ;
Yong, Chung Lip ;
Sukari, Mohamed Aspollah ;
Kamalidehghan, Behnam .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 :1193-1208
[2]   Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy [J].
Ahmed, Mahiuddin ;
Cheung, Nai-Kong V. .
FEBS LETTERS, 2014, 588 (02) :288-297
[3]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[4]   Gold nanorods: Their potential for photothermal therapeutics and drug delivery, tempered by the complexity of their biological interactions [J].
Alkilany, Alaaldin M. ;
Thompson, Lucas B. ;
Boulos, Stefano P. ;
Sisco, Patrick N. ;
Murphy, Catherine J. .
ADVANCED DRUG DELIVERY REVIEWS, 2012, 64 (02) :190-199
[5]   Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+breast cancer cell proliferation and stem cell survival [J].
Baker, Andrew ;
Wyatt, Debra ;
Bocchetta, Maurizio ;
Li, Jun ;
Filipovic, Aleksandra ;
Green, Andrew ;
Peiffer, Daniel S. ;
Fuqua, Suzanne ;
Miele, Lucio ;
Albain, Kathy S. ;
Osipo, Clodia .
ONCOGENE, 2018, 37 (33) :4489-4504
[6]   Cancer stem cells revisited [J].
Batlle, Eduard ;
Clevers, Hans .
NATURE MEDICINE, 2017, 23 (10) :1124-1134
[7]   Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis [J].
Battula, Venkata Lokesh ;
Shi, Yuexi ;
Evans, Kurt W. ;
Wang, Rui-Yu ;
Spaeth, Erika L. ;
Jacamo, Rodrigo O. ;
Guerra, Rudy ;
Sahin, Aysegul A. ;
Marini, Frank C. ;
Hortobagyi, Gabriel ;
Mani, Sendurai A. ;
Andreeff, Michael .
JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (06) :2066-2078
[8]   An NQO1-and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone [J].
Bey, Erik A. ;
Bentle, Melissa S. ;
Reinicke, Kathryn E. ;
Dong, Ying ;
Yang, Chin-Rang ;
Girard, Luc ;
Minna, John D. ;
Bornmann, William G. ;
Gao, Jinming ;
Boothman, David A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (28) :11832-11837
[9]   What makes tumors multidrug resistant? [J].
Borst, Piet ;
Jonkers, Jos ;
Rottenberg, Sven .
CELL CYCLE, 2007, 6 (22) :2782-2787
[10]   Light-controlled endosomal escape of the novel CD133-targeting immunotoxin AC133-saporin by photochemical internalization - A minimally invasive cancer stem cell-targeting strategy [J].
Bostad, Monica ;
Olsen, Cathrine Elisabeth ;
Peng, Qian ;
Berg, Kristian ;
Hogset, Anders ;
Selbo, Pal Kristian .
JOURNAL OF CONTROLLED RELEASE, 2015, 206 :37-48